Rituximab dose-escalation trial in chronic lymphocytic leukemia

Area of Science:

• Hematology
• Oncology
• Immunotherapy

Background:

• Chronic lymphocytic leukemia (CLL) is a mature B-cell lymphoid leukemia.
• Rituximab is a monoclonal antibody targeting CD20 surface expression.

Purpose of the Study:

• Determine the maximum-tolerated dose (MTD) of rituximab in CLL patients.
• Evaluate first-dose reactions in patients with high lymphocyte counts.
• Assess rituximab efficacy at escalated doses.

Main Methods:

• Dose-escalation trial involving 50 patients (40 CLL, 10 other B-cell leukemias).
• Four weekly infusions of rituximab, starting at 375 mg/m², escalating to 2,250 mg/m².
• Monitoring for toxicity and treatment response.

Main Results:

• Overall response rate was 40%, with higher responses at escalated doses (75% at 2,250 mg/m²).
• Severe first-dose reactions were rare in CLL (2%) but common in other B-cell leukemias (50%).
• Median time to disease progression was 8 months; myelosuppression and infections were infrequent.

Conclusions:

• Rituximab demonstrates significant efficacy in CLL at higher dose levels.
• Higher rituximab doses correlate with improved response rates in CLL.
• Severe first-dose reactions are uncommon in CLL, unlike in other B-cell leukemias.